An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2017
At a glance
- Drugs REP 2139-Ca (Primary) ; Interferon alpha-2a; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors REPLICor
- 20 Apr 2017 Results published in a Replicor media release.
- 20 Apr 2017 According to a Replicor media release, results from this trial were presented at the European Association for the Study of the Liver (EASL) 2017 annual meeting.
- 20 Feb 2017 According to a Replicor media release, an updated interim analysis from this trial was presented at the Asia Pacific Association for the Study of Liver (APASL) 2017.